Metformin protects against diabetes-induced heart injury and dunning prostate cancer model

Abstract

In this study, both diabetes and Dunning prostate cancer were induced for the first time in Copenhagen rats in vivo. Thus, the effects of metformin against heart tissue damage of these rats were investigated by biochemical methods. Dunning prostate cancer was induced in Copenhagen rats using high metastatic MAT-LyLu cells. The rats were divided as follows: Control group: only injected with 0.9% NaCl for 14 days; Diabetic group: only injected single dose of streptozotocin (STZ) (65 mg/kg); Cancer group: subcutaneously (s.c) inoculated with 2 x 10⁴ MAT-LyLu cells only; Diabetic + cancer (DC) group: inoculated with 2 x 10⁴ MAT-LyLu cells and STZ injection, Cancer + metformin (CM) group: injected with metformin for 14 days after Mat-LyLu cells application; Diabetic + cancer + metformin (DCM) group: metformin administered for 14 days together with STZ and Mat-LyLu cells. At the end of the experimental period, heart tissues were taken. Reduced glutathione and total antioxidant status levels in heart tissues were decreased, whereas lipid peroxidation, advanced oxidized protein products, nitric oxide, homocysteine, and reactive oxygen species levels, total oxidant status and catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase and xanthine oxidase activities increased in the diabetic, cancer and DC groups. Treatment with metformin reversed these effects. In conclusion, the present study shows that metformin has a protective effect against heart tissue damage in STZ-induced diabetic rats with Dunning prostate cancer.

Keywords

Diabetes Dunning prostate cancer metformin oxidative stress parameters heart damage

Introduction

It is expected that 44140 new cancer cases will be diagnosed in 2020 when compared with new cases diagnosed in 2019. Thus, prostate cancer (PCa) is estimated to be on the first rank among the newly diagnosed cancer cases in 2019. On the other hand, prostate cancer is expected to be the second most common cause of cancer related deaths after lung/bronchial cancer.^1,2

PCa is a disease of the prostate gland, which is located just below the bladder and surrounds the urethra.³ It has been indicated that acinar adenocarcinoma developing in the glandular cells of the prostate is the main type of PCa that accounts for about 99% of cases. Besides, there are much less common types of PCa such as ductal adenocarcinoma, urothelial, squamous cell, neuroendocrine (carcinoid) tumors and sarcomas.⁴

In general, diabetes is a multifactorial disease that is characterized by insulin deficiency or resistance, which lead to hyperglycaemia. The persistence of hyperglycaemia causes a further increase in oxidative stress status due to increased free radical formation. Increased cellular oxidative stress elevates the risk of cancer by damaging important biomolecules such as DNA.⁵ Both cancer and diabetes are prevalent diseases whose incidence is increasing globally. Diabetes is associated with high risk factors that progress into many types of cancer, especially hepatocellular carcinoma,^6,7 breast,⁸ lung, colorectal, gastric and PCa.^9,10 Diabetes also complicates the prognosis of cardiovascular heart disease and increases the mortality rate associated with coronary heart disease.¹¹ Both type 1 diabetic (T1DM) and type 2 diabetic (T2DM) patients are at a high risk of developing heart diseases.¹² Moreover, individuals with T2DM have a markedly higher risk of cardiovascular morbidity and mortality as compared to healthy subjects.¹³ The risk of developing heart failure in healthy individuals has been reported to be less than two-times that of diabetic patients.¹⁴ Therefore, increased prevalence of diabetes contributes significantly to the etiology of cardiovascular dysfunction, with heart failure increasingly observed in diabetic individuals.¹⁵ Recent studies suggest that chronic hyperglycaemia is associated with ROS-induced oxidative stress, which in turn plays a crucial role in the development and progression of impaired cardiac function.^16
–18 In a population-based study, cancer patients were found to have a higher risk of dying from cardiovascular disease and the risk is negatively related to the diagnosis at an early stage.¹⁹

Metformin (a biguanide drug) is a commonly used as an oral antihyperglycaemic agent that is not only well-tolerated, but easily accessible and is the first treatment option for T2DM.²⁰ Moreover, metformin has been used as a beneficial drug in the treatment of T2DM in Europe for over 60 years, and in USA for over 25 years. The main reason for the continues use of this drug in T2DM is that it has not enhanced insulin-sensitivity, but also glucose-lowering effect in hepatic cells.^21,22 Beyond its antidiabetic role, metformin treatment is associated with decreased cancer incidence and as well decreased cancer-related mortality.^23,24

In the past decade, clinical studies have shown that diabetic subjects may have a decreased risk of PCa.²⁵ On the other hand, recent data suggested that the decrease in risk of PCa is associated with the use of antidiabetic drugs like metformin.²⁶ The main purpose of this study was to determine the possible effect of metformin on heart damage in STZ-induced diabetic rats with Dunning PCa.

Materials and methods

Animals

In this study, Copenhagen breed adult rats obtained from “TÜBİTAK MAM Genetic Engineering and Biotechnology Institute” were used. All experimental protocols were approved by the Animal Care and Use Committee of the Istanbul University, Istanbul, Turkey (2014/28-the ethics committee decision number). Rats weighing 150–220 g were housed individually in a light and temperature-controlled room on a 12 h/12 h light–dark cycle and fed a standard pellet lab chow.

Cell culture

Dunning model strongly metastatic Mat-LyLu cells were grown in RPMI culture medium (RPMI-1640, Gibco; Life Technologies, USA), supplemented with 1% fetal bovine serum (FBS) (Gibco), 2 mM L-glutamine (Gibco; Life Technologies, USA) and 250nM dexamethasone (Sigma; Sigma-Aldrich, USA).^27,28 Cells were maintained in a 37°C/5% CO₂ incubator.

Pharmacological agents

Streptozotocin (STZ) (65mg/kg) (Sigma, SB.S0130-1G) was diluted in 1 mL of +4°C physiological saline (PS) and injected intraperitoneally (i.p.) into rats in order to induce diabetes. Fasting blood glucose of rats left unfed was examined at the 72nd hour, those with fasting glucose of 200 mg/dL were considered diabetic. Metformin (250 mg/kg) (Sigma, D150959-5G) was dissolved in 0.2 mL PS at +4°C and given to the rats systemically via gavage.

Experimental design

Experimental rats were randomly split into six groups as follows; I) Control group: only injected with 0.9% PS for 14 days, II) Diabetic group: only injected single dose of streptozotocin (STZ) (65mg/kg),²⁹ III) Cancer group: subcutaneously (s.c) inoculated with 2 x 10⁴ MAT-LyLu cells only, IV) Diabetic + cancer (DC) group: inoculated with 2 x 10⁴ MAT-LyLu cells and STZ injection, V) Cancer + metformin (CM) group: injected with metformin³⁰ for 14 days after Mat-LyLu cells application VI) Diabetic + cancer + metformin (DCM) group: metformin administered for 14 days together with STZ and Mat-LyLu cells. The 2 x 10⁴ MAT-LyLu cells were inoculated into the upper-right extremities of the rats in order to create PCa after the diabetic assay. The experiment was terminated on the 14th day to procure early PCa.³¹ At the end of the study, all animals were dissected under ketamine hydrochloride (Ketalar®, Eczacıbaşı) and xylazine HCl (Alfazyne®, Holland) anesthesia.

Biochemical analyses

Heart tissue samples were taken and immediately washed in ice-cold with PS solution and homogenized in PS with a glass homogenizer to make up to 10% homogenate (w/v). These homogenates were centrifuged at 10000×g at +4°C for 10 minutes. After centrifugation, clear supernatants were collected and the pellets were discarded. The clear supernatants were used for biochemical analyses. Reduced glutathione (GSH), lipid peroxidation (LPO), advanced oxidized protein products (AOPP), and nitric oxide (NO) levels were determined according to by the methods of Beutler³² using Ellman’s reagent, Ledwozyw et al.,³³ Witko-Sarsat et al.,³⁴ and Miranda et al.,³⁵ respectively. Homocysteine (HCys) level was assayed using ELISA kit according to instructor’s manual. Reactive oxygen species (ROS) levels, total oxidant status (TOS), and total antioxidant status (TAS) in the heart tissues were analyzed according to Zhang et al.,³⁶ Erel,^37,38 respectively. Catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione-S-transferase (GST) activities were assessed by the methods described by Aebi,³⁹ Mylorie et al.,⁴⁰ Paglia and Valentine⁴¹ and modified by Wendel,⁴² Beutler,⁴³ and Habig and Jacoby,⁴⁴ respectively. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assayed according to Reitman and Frankel.⁴⁵ Lactate dehydrogenase (LDH) and xanthine oxidase (XO) activities were estimated according to Bais and Philcox⁴⁶ and Corte and Stirpe,⁴⁷ respectively. The protein content in the supernatants was estimated according to Lowry et al.⁴⁸ method using Bovine Serum Albumin (BSA) as standard.

Statistics

Statistical analysis was performed using GraphPad Prism 6.0 (GraphPad Software, San Diego, California, USA). All data were expressed as means ± standard deviation (SD). The results were evaluated using an unpaired t-test and analysis of variance (ANOVA) followed by Tukey’s multiple comparison tests. A p value of less than 0.05 represented significance.

Results

Reduced glutathione (GSH) and lipid peroxidation (LPO) levels are shown in Figure 1. The levels of GSH in diabetic and DC group were slightly elevated, but significantly lower in cancer group than the control group (p < 0.0001). On the other hand, metformin treatment to DC group resulted in a slighter declined, but caused a remarkable increase in heart GSH levels of the cancer group (p < 0.0001) (Figure 1). LPO levels in diabetic group was insignificantly elevated, whereas in the cancer and DC group, it was remarkably raised compared to the control group (p < 0.01 and p < 0.0001). Supplementation of metformin to both cancer and DC groups resulted in a significant decrease in the heart LPO levels (p < 0.05 and p < 0.0001) (Figure 1).

Figure 1.

Effect of metformin on heart tissue glutathione and lipid peroxidation levels in diabetic, cancer and DC groups of rats: (a) GSH, (b) LPO. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; GSH: Reduced glutathione; LPO: Lipid peroxidation; MDA: Malondialdehyde.

Advanced oxidized protein products (AOPP), nitric oxide (NO), and homocysteine (HCys) levels are presented in Figure 2. AOPP levels in diabetic, cancer and DC groups were significantly increased when compared to control groups (p < 0.001, p < 0.0001 and p < 0.01). There was a significant decrease in the level of AOPP in cancer group (p < 0.0001), but an insignificant decrease in DC group when metformin was administered to cancer and DC groups (Figure 2). NO and HCys levels in the heart homogenates of diabetic, cancer and DC groups were notably increased as compared with control group (p < 0.0001, p < 0.001 and p < 0.05). The administration of metformin to cancer and DC groups gave rise to a notable decrease in NO and HCys levels respectively (p < 0.001 and p < 0.01) (Figure 2).

Figure 2.

Effects metformin on AOPP, NO, and HCys levels in diabetic, cancer and DC groups of rats: (a) AOPP, (b) NO, (C) HCys. All the values are expressed as mean ± SD. DC: Diabetic+cancer; DCM: Diabetic+cancer+metformin; AOPP: Advanced oxidized protein products; NO: Nitric oxide; HCys: Homocysteine.

Reactive oxygen species (ROS), total oxidant status (TOS) and total antioxidant status (TAS) levels are shown in Figure 3. A remarkable elevation of ROS activity and TOS levels were observed in diabetic (p < 0.001 and p < 0.01), cancer (p < 0.0001 and p < 0.001) and DC groups (p < 0.0001) respectively when compared to control rats (Figure 3). On the contrary, TAS level remarkably decreased in diabetic (p < 0.0001), cancer (p < 0.001) and DC group (p < 0.01) when compared to control rats. Supplementation of metformin in both cancer and DC groups notably reversed these effects (Figure 3).

Figure 3.

Effects of metformin on ROS, TOS, and TAS levels in diabetic, cancer and DC groups of rats: (a) ROS, (b) TOS, (c) TAS. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; ROS: Reactive oxygen species; TOS: Total oxidant status; TAS: Total antioxidant status.

Catalase (CAT) and superoxide dismutase (SOD) activities of all groups are shown in Figure 4. A statistically significant elevation of both CAT and SOD activities were observed in diabetic (p < 0.0001 and p < 0.01), cancer (p < 0.001 and p < 0.05) and DC (p < 0.0001 and p < 0.001) groups as compare to control group. The administration of metformin to the cancer and DC groups noticeably dropped CAT and SOD activities (p < 0.01 and p < 0.001) (Figure 4).

Figure 4.

Effects of metformin on heart tissue CAT and SOD activities in diabetic, cancer and DC groups of rats: (a) CAT, (b) SOD. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; CAT: Catalase; SOD: Superoxide dismutase.

Glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione-S-transferase (GST) activities of heart tissues of all groups were presented in Figure 5. In the heart of diabetic, cancer and DC rats, GPx activity was significantly increased when compared to the control group (p < 0.05 and p < 0.0001). After supplementation with metformin to both cancer and DC group, a significant decrease in GPx activity (p < 0.0001) (Figure 5) was noticed. We observed a notable increase in GR and GST activities all experimental groups when compared to control rats (p < 0.01, p < 0.0001 and p < 0.05). Metformin treatment resulted to a remarkable decrease in GR (p < 0.0001 and p < 0.001) and GST activities in both cancer and DC groups (p < 0.0001) (Figure 5).

Figure 5.

Effects of metformin on GPx, GR and GST activities in diabetic, cancer and DC groups of rats: (a) GPx, (b) GR, (c) GST. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; GPx: Glutathione peroxidase; GR: Glutathione reductase; GST: Glutathione-S-transferase.

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities are presented in Figure 6. It was observed that ALT and AST activities were significantly elevated in diabetic, cancer and DC group as compared to control rats (p < 0.0001 and p < 0.05). Metformin administration to cancer and DC group significantly reverted the activities of both ALT and AST (p < 0.001, p < 0.0001 and p < 0.01) (Figure 6).

Figure 6.

Effects of metformin on ALT and AST activities in diabetic, cancer and DC groups of rats: (a) ALT, (b) AST. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; ALT: Alanin aminotransferase; AST: Aspartate aminotransferase.

Lactate dehydrogenase (LDH) and xanthine oxidase (XO) activities of all experimental groups are presented in Figure 7. In diabetic, cancer and DC groups, we observed a notable increase in LDH (p < 0.001 and p < 0.0001) and XO activities (p < 0.0001, p < 0.001, and p < 0.01) when compared to control rats. The administration of metformin to cancer group caused a significant decrease in the LDH (p < 0.0001) and XO activities of cancer and DC groups (p < 0.001 and p < 0.05) (Figure 7).

Figure 7.

Effects of metformin on LDH and XO activities in diabetic, cancer and DC groups of rats: (a) LDH, (b) XO. All the values are expressed as mean ± SD. DC: Diabetic+cancer; CM: Cancer+metformin; DCM: Diabetic+cancer+metformin; LDH: Lactate dehydrogenase; XO: Xanthine oxidase.

Discussion

Diabetes and cancer continue to be among the most important health problems in terms of both morbidity and mortality, and are becoming increasingly critical day by day. However, diabetes alone and/or its related factors are a possible micro-environment that can trigger formation or progression of cancer.⁴⁹ It is stated that diabetic individuals have higher risk of death due to cancer as compared to patients without diabetes.⁵⁰ Scientists and research groups all over the world are making great efforts to find the treatment of both diabetes and various types of cancers. For this purpose, they are constantly working on new drugs or molecules that may be useful in medication for use in treatment. Upon literature search, we found little or no information on the possible beneficial effects of metformin on heart tissues of STZ-induced diabetic rats with Dunning prostate cancer model.

Under normal physiological conditions, there is a balance between reactive oxygen species (ROS) that are constantly being formed in cells and antioxidants that neutralize them. Disruption of this balance in favors of ROS, i.e. oxidative stress set in which is characterized by the accumulation of cellular oxy-radicals or compromised endogenous defense systems.⁵¹

Reduced GSH is a major intracellular component of antioxidant defense, which neutralizes ROS as well as regulates cellular survival by offering redox homeostasis in a variety of tumors including lung, breast, colon and PCa.^52,53 On the other hand, quantification of malondialdehyde (MDA) levels as secondary metabolite of LPO in either serum or tissue homogenates are useful biomarker for assessing oxidative damage.⁵⁴ In the present study, we observed that GSH levels apparently declined in the cancer group only, but moderately increased in both diabetic and DC groups, whereas LPO levels were notably elevated when compared to control group. Depletion of GSH and elevation of LPO levels in experimental groups may be as a result of increased ROS formation. Hajra et al.⁵⁵ stated that doxorubicin-induced cardiotoxicity caused a remarkable decline of GSH levels, whereas LPO levels significantly increased. These outcomes were similar to the LPO levels of cardiac tissues of diabetic rats reported by Naderi et al.,⁵⁶ and Aju et al.,⁵⁷ and of breast cancer subjects reported by Kangari et al.⁵⁴ In our study, it was observed that the levels of both GSH and LPO were almost normalized to levels similar to that of the control group after metformin treatment. The attenuating properties of metformin may be due to its antitumor, antioxidant, and antihyperglycaemic effects.^58,59

AOPPs are oxidized plasma proteins of albumin and its aggregates, which are important biomarkers for determining oxidative stress. It is observed that increased AOPP levels may be an independent risk factor of atherosclerotic plaques in coronary artery disease.⁶⁰ It is also suggested that AOPP’s accumulation may be linked to vascular lesions in diabetes, chronic renal insufficiency and atherosclerosis.⁶¹ NO, a ubiquitous short-lived signaling molecule in nature and a free radical as well as, has a vasodilating effect under physiological circumstances in the vascular endothelium.⁶² In addition, NO plays a dual role in cancer development depending on its concentration or where it is formed. It may also have a tumouricidal or tumour-inhibiting effect.^63,64 HCys is a non-proteinogen α-amino acid that is produced from methionine, an elevation of its levels is clinically associated with primary risk factor for coronary and cardiovascular mortality.⁶⁵ In the current study, we found that the levels of AOPP, NO and HCys in cancer, diabetic and DC group rats were significantly higher than control rats. The alteration of AOPP, NO and HCys levels may be due to altered oxidant/antioxidant balance which favored oxidants or the progression of the inflammatory process. Similar results were reported by Škvařilová et al.⁶⁶ for AOPP, by Stadler et al.⁶⁷ for NO and by Beyramzadeh et al.⁶⁸ for HCys, respectively. We observed that all these parameters were nearly restored by metformin administration to the cancer, diabetic and DC rats. Metformin may be responsible for decreasing protein oxidation, as well as HCys levels in the heart. Our findings are in accordance with that of Meaney et al.⁶⁹ and Kelleni et al.⁷⁰

To assess the redox status, we focused on ROS activity, TOS and TAC levels. These parameters are frequently studied because they are useful biomarkers for evaluating the biochemical and pathophysiological conditions underlying various diseases associated with oxidative stress.^71,72 In the present study, we found that ROS and TOS levels in diabetic, cancer and DC groups were higher than values found in control group, whereas TAS level in these group was lower than in control rats. Our findings are consistent with the Bozkurt et al.⁷¹ and Zińczuk et al.⁷³ Metformin treatment to cancer and DC groups resulted in restoration of oxidant/antioxidant status in heart tissues of rats, which may be related to the anticancer and antidiabetic effects of metformin.

The antioxidant enzyme system is a complex antioxidant mechanism ubiquitously found in cells against harmful effects of free radicals on tissues. SOD, CAT, GPx, GR, and GST are among the basic and first line of defense against deleterious effects of free radicals in the cell.⁷⁴ SOD catalyzes the dismutation of superoxide radical to H₂O₂. Produced by dismutation of superoxide radicals, H₂O₂ is converted into H₂O by CAT and/or GPx. During the reaction catalyzed by GPx, GSH is oxidized to it disulphide i.e. GSSG. On the other hand, GSSG is reduced by the catalytic action of the GR enzyme.⁷⁵ In our study, SOD, CAT, GPx, GR and GST activities in diabetic, cancer and DC groups were found to elevate as compared to control rats. These results suggest the increased activity of these first line antioxidant enzymes may be due to adaptive response against overproduction of ROS in heart tissues of both diabetes and PCa models. In a by Stefek et al.,⁷⁶ both SOD and CAT activities were increased in myocardium of diabetic rats. Kumar et al.⁷⁷ conducted a study on effects of multiple antioxidants on cardiac complications and they found that CAT activities were higher in the test than in control rats. Similar findings were reported by Tchamgoue et al.⁷⁸ On the other hand, Kotrikadze et al.⁷⁹ and Taheri et al.⁸⁰ reported that GPx and GR activities were sharply increased in prostate tumor and T2DM patients, respectively. GPx activities were found to rise in prostate tissues of diabetic rats.⁸¹ Moreover, it was found that both GPx and GR activities significantly increased in gastrocnemius muscle of diabetic rats.⁸² It was shown that GST activities in myocardium tissues were notably increase in diabetic rats.⁸³ In the present study, metformin administration reversed the alterations of these defensive enzymes. The reason for the superior effect of metformin may be a compensatory response to oxidative stress and possibly the increased expression of antioxidant enzymes in tissues of rats.⁸⁴

ALT and AST have been used as diagnostic biomarkers for assessing both liver and heart tissue necrosis.^85,86 In the current study, both ALT and AST activities significantly increased in all experimental groups as compared to control group. Our findings were in accordance with reports of Bayramoglu et al.⁸⁷ and Hajra et al.⁵⁵ Metformin administration restored the activities of these enzymes in heart tissues of experimental rats. This indicates that metformin reduces oxidative stress, leading to reduced formation of ROS. The findings of the present study are in accordance with results of previous studies.^78,88

LDH, a soluble cytoplasmic enzyme, is ubiquitously found in almost all cells. It is released into extracellular space when the integrity of plasma membrane is compromised for any reason.⁸⁹ Its increased activity is an important biomarker of tissue damage especially the cardiac tissue.⁹⁰ XO is a well-known enzyme that is responsible for generation of free radicals when it catalyzes the conversion of hypoxanthine and xanthine to uric acid.⁹¹ Enhanced XO activity in vascular endothelium is association with elevated serum uric acid levels which result in oxidative damage. Moreover, the activity of vascular endothelium-bounded XO is reported to increase more than two-fold in both heart failure and coronary arteries disease when compared to healthy subjects.⁹² In the current study, we found that LDH and XO activities in cancer, diabetic and DC groups of rats significantly increased as compared to control rats. In a study by Farshid et al.⁹³ and Aliciguzel et al.,⁹⁴ increase in LDH and XO activities in heart tissues in diabetic rats were reported. Both LDH and XO activities notably diminished when metformin was administered to diabetic, cancer and DC groups. In our study, MDA levels increased in all damaged heart tissues. In addition, the increased level of MDA may be associated with the activity of XO which is an important free radical source. Therefore, metformin may have reduced MDA level and thus XO activity with its antioxidant effect. Our results were consistent with the findings of Kelleni et al.⁷⁰ and Cosić et al.⁹⁵

Conclusions

In the present finding, the administration of metformin in both STZ-induced diabetes and Dunning PCa model resulted in positive changes on total oxidant-antioxidant status. Metformin treatment also exhibited beneficial effect by altering the activities of first line antioxidant defense enzyme in heart tissues of rats. In conclusion, it can be suggested that metformin may recuperate heart damage by stabilizing oxidative stress parameters as well as cardiac enzyme activities in STZ-induced diabetes and Dunning PCa model via its antioxidant, antitumor and anti-inflammatory effects.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

BB Bayrak

P Koroglu

References

Siegel

Miller

Jemal

. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7–34.

Siegel

Miller

Jemal

. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.

Rawla

. Epidemiology of prostate cancer. World J Oncol 2019; 10: 63–89.

Brausi

Hoskin

Andritsch

, et al. ECCO Essential requirements for quality cancer care: Prostate cancer. Crit Rev Oncol Hematol 2020; 148: 102861.

Abudawood

Tabassum

Almaarik

, et al. Interrelationship between oxidative stress, DNA damage and cancer risk in diabetes (Type 2) in Riyadh, KSA. Saudi J Biol Sci 2020; 27: 177–183.

Wang

Gao

. Diabetes mellitus and risk of hepatocellular carcinoma. Biomed Res Int 2017; 2017: 5202684.

Mantovani

Targher

. Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. Ann Transl Med 2017; 5: 270.

Maskarinec

Sadakane

Sugiyama

, et al. Type 2 diabetes, obesity, and breast cancer risk among Japanese women of the atomic bomb survivor cohort. Cancer Epidemiol 2019; 60: 179–184.

Yeung

SLA

Schooling

. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. BMJ Open Diabetes Res Care 2019; 7: e000872.

10.

Baglia

Cui

Zheng

, et al. Diabetes medication use in association with survival among patients of breast, colorectal, lung, or gastric cancer. Cancer Res Treat 2019; 51: 538–546.

11.

Mohamed

Alaa

, et al. Contribution of non traditional cardiovascular risk factors to the cardiovascular disease in patient with type 2 diabetes. Zagazig University Med J 2020; 26: 1–6.

12.

Khan

Anker

Januzzi

Jr , et al. Heart failure epidemiology in patients with diabetes mellitus without coronary heart disease. J Card Fail 2019; 25: 78–86.

13.

Larsson

Wallin

Håkansson

, et al. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol 2018; 262: 66–70.

14.

Kenny

Abel

. Heart failure in type 2 diabetes mellitus: impact of glucose lowering agents, heart failure therapies and novel therapeutic strategies. Circ Res 2019; 124: 121–141.

15.

Keates

Mocumbi

Ntsekhe

, et al. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol 2017; 14: 273–293.

16.

Giacco

Brownlee

, Oxidative stress and diabetic complications. Circ Res 2010; 107: 1058–1070.

17.

Kayama

Raaz

Jagger

, et al. Diabetic cardiovascular disease induced by oxidative stress. Int J Mol Sci 2015; 16: 25234–25263.

18.

Johnson

Sangweni

Mabhida

, et al. An in vitro study on the combination effect of metformin and N-acetyl cysteine against hyperglycaemia-induced cardiac damage. Nutrients 2019; 11: E2850.

19.

Sturgeon

Deng

Bluethmann

, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40: 3889–3897.

20.

Ferlay

Soerjomataram

Dikshit

, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359–386.

21.

Pernicova

Korbonits

. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014; 10: 143–156.

22.

. Current understanding of metformin effect on the control of hyperglycemia in diabetes. J Endocrinol 2016; 228: R97–106.

23.

Kim

Lee

Chun

, et al. Metformin reduces the risk of cancer in patients with type 2 diabetes: an analysis based on the Korean national diabetes program cohort. Medicine, 2018; 97: e0036.

24.

Kuo

Sung

Hsieh

, et al. Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: a nationwide population-based cohort study. Cancer Med 2019; 8: 2514–2523.

25.

Wang

Liu

Yan

, et al. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies. Eur J Cancer Prev 2020; 29: 42–52.

26.

Jiao

Wang

Luo

. Preventive and (neo) adjuvant therapeutic effects of metformin on cancer [Online First], (2020) IntechOpen. DOI: 10.5772/intechopen.91291.

27.

Grimes

Fraser

Stephens

, et al. Differential expression of voltage-activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro. FEBS Lett 1995; 369: 290–294.

28.

Bugan

Zeynep Karagoz

Altun

, et al. Gabapentin, an analgesic used against cancer-associated neuropathic pain: effects on prostate cancer progression in an in vivo rat model. Basic Clin Pharmacol Toxicol 2016; 118: 200–207.

29.

Pabitra

Krishnendu

Parames

. Mangiferin attenuates diabetic nephropathy by inhibiting oxidative stress mediated signaling cascade, TNF-α related and mitochondrial dependent apoptotic pathways in streptozotocin-induced diabetic rats. PLoS One 2014; 9: e107220.

30.

Salama

Schaalan

Elkoussi

, et al. Potential utility of sodium selenate as an adjunct to metformin in treating type II diabetes mellitus in rats: a perspective on protein tyrosine phosphatase. Biomed Res Int 2013; 2013: 231378.

31.

Mossine

Chopra

Mawhinney

. Interaction of tomato lycopene and ketosamine against rat prostate tumorigenesis. Cancer Res 2008; 68: 4384–4391.

32.

Beutler

. Glutathione in red cell metabolism: a manual of biochemical methods. 2nd edn. New York, NY: Grune and Stratton, 1975, pp. 112–114.

33.

Ledwozyw

Michalak

Stepien

, et al. The relationship between plasma triglycerides, cholesterol, total lipids and lipid peroxidation products during human atherosclerosis. Clin Chim Acta 1986; 155: 275–283.

34.

Witko-Sarsat

Friedlander

Capeillère-Blandin

, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313.

35.

Miranda

Espey

Wink

. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide, 2001; 5: 62–71.

36.

Zhang

Chen

, et al. Protective effects of Danshen injection against erectile dysfunction via suppression of endoplasmic reticulum stress activation in a streptozotocin-induced diabetic rat model. BMC Complement Altern Med 2018; 18: 343.

37.

Erel

. A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005; 38: 1103–1111.

38.

Erel

. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004; 37: 277–285.

39.

Aebi

. Catalase in vitro. Methods Enzymol 1984; 105: 121–126.

40.

Mylorie

Collins

Umbles

, et al. Erythrocyte superoxide dismutase activity and other parameters of copper status in rats ingesting lead acetate. Toxicol Appl Pharmacol 1986; 82: 512–520.

41.

Paglia

Valentine

. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158–169.

42.

Wendel

. Glutathione peroxidase. Methods Enzymol 1981; 77: 325–333.

43.

Beutler

. Red cell metabolism. A manual of biochemical methods. Vol. 12. London: Academic Press, 1971, pp. 68–70.

44.

Habig

Jacoby

. Assays for differentiation of glutathione-S-transferases. Methods Enzymol 1981; 77: 398–405.

45.

Reitman

Frankel

. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am J Clin Pathol 1957; 28: 56–63.

46.

Bais

Philcox

. Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 8. IFCC Method for Lactate Dehydrogenase (l-Lactate: NAD+Oxidoreductase, EC 1.1.1.27). International Federation of Clinical Chemistry (IFCC). Eur J Clin Chem Clin Biochem 1994; 32: 639–655.

47.

Corte

Stirpe

. Regulation of xanthine oxidase in rat liver: modifications of the enzyme activity of rat liver supernatant on storage at 20 degrees. Biochem J 1968; 108: 349–351.

48.

Lowry

Rosebrough

Farr

A.L

, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275.

49.

Singh

Shrinet

Tripathi

, et al. Risk established between type II diabetes mellitus and cancer: a review. J Sci Res Banaras Hindu University 2019; 63: 69–77. ISSN: 0447-9483.

50.

Harding

Andes

Gregg

, et al. Trends in cancer mortality among people with vs without diabetes in the USA, 1988–2015. Diabetologia 2020; 63: 75–84.

51.

Birben

Sahiner

Sackesen

, et al., Oxidative stress and antioxidant defense. World Allergy Organ J 2012; 5: 9–19.

52.

Bansal

Simon

. Glutathione metabolism in cancer progression and treatment resistance. J Cell Biol 2018; 217: 2291–2298.

53.

Spampinato

Sferrazzo

Pittalà

, et al. Non-competitive heme oxygenase-1 activity inhibitor reduces non-small cell lung cancer glutathione content and regulates cell proliferation. Mol Biol Rep 2020; 47:1949–1964.

54.

Kangari

Farahany

Golchin

, et al. Enzymatic antioxidant and lipid peroxidation evaluation in the newly diagnosed breast cancer patients in Iran. Asian Pac J Cancer Prev 2018; 19: 3511–3515.

55.

Hajra

Patra

Basu

, et al. Prevention of doxorubicin (DOX)-induced genotoxicity and cardiotoxicity: Effect of plant derived small molecule indole-3-carbinol (I3C) on oxidative stress and inflammation. Biomed Pharmacother 2018; 101: 228–243.

56.

Naderi

Mohaddes

Mohammadi

, et al. Preventive effects of garlic (Allium sativum) on oxidative stress and histopathology of cardiac tissue in streptozotocin-induced diabetic rats. Acta Physiol Hung 2015; 102: 380–390.

57.

Aju

Rajalakshmi

Mini

. Protective role of Moringa oleifera leaf extract on cardiac antioxidant status and lipid peroxidation in streptozotocin induced diabetic rats. Heliyon 2019; 5: e02935.

58.

Zaidi

Gandhi

Joshi

, et al. The anticancer potential of metformin on prostate cancer. Prostate Cancer Prostatic Dis 2019; 22: 351–361.

59.

Yamashita

Kato

Fujihara

, et al. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest. Anticancer Drugs 2020; 31: 231–240.

60.

Huang

, et al. The characteristics and roles of advanced oxidation protein products in atherosclerosis. Cardiovasc Toxicol 2017; 17: 1–12.

61.

Guo

Niu

Hou

, et al. Vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 2008; 10: 1699–1712.

62.

Alimoradi

Greish

Gamble

, et al. Controlled delivery of nitric oxide for cancer therapy. Pharm Nanotechnol 2019; 7: 279–303.

63.

Choudhari

Chaudhary

Bagde

, et al., Nitric oxide and cancer: a review. World J Surg Oncol 2013; 11: 118.

64.

Mishra

Patel

Banerjee

. Nitric oxide and S-nitrosylation in cancers: Emphasis on breast cancer. Breast Cancer (Auckl) 2020; 14: 1178223419882688.

65.

Matetzky

Freimark

Ben-Ami

, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med 2003; 163: 1933–1937.

66.

Škvařilová

Bulava

Stejskal

, et al. Increased level of advanced oxidation products (AOPP) as a marker of oxidative stress in patients with acute coronary syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2005; 149: 83–87.

67.

Stadler

Jenei

Bölcsházy

, et al. Increased nitric oxide levels as an early sign of premature aging in diabetes. Free Radic Biol Med 2003; 35: 1240–1251.

68.

Beyramzadeh

Ansari

MHK

Azimzadeh

, et al. Protective effects of vitamin E on diabetes-induced oxidative stress status and homocysteine in the rat heart. J Pharm Pharmacol 2017; 5: 708–716.

69.

Meaney

Vela

Samaniego

, et al. Metformin, arterial function, intima–media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin Exp Pharmacol Physiol 2008; 35: 895–903.

70.

Kelleni

Amin

Abdelrahman

. Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: impact of oxidative stress, inflammation, and apoptosis. J Toxicol 2015; 2015: 424813.

71.

Bozkurt

Gürsul

Aydin

, et al. The evaluation of oxidative stress parameters in the benign prostatic hyperplasia, prostatitis and prostate cancer. Ortadogu Tıp Dergisi, 2019; 11: 315–321.

72.

Zhong

, et al. Total antioxidant capacity and pancreatic cancer incidence and mortality in the prostate, lung, colorectal and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. Epub ahead of print 12 Feb 2020. DOI: 10.1158/1055-9965.EPI-19-1511.

73.

Zińczuk

Maciejczyk

Zaręba

, et al.

Antioxidant barrier, redox status, and oxidative damage to biomolecules in patients with colorectal cancer. Can malondialdehyde and catalase be markers of colorectal cancer advancement?

Biomolecules 2019; 9: E637.

74.

Aslankoç

Demirci

İnan

, et al. The role of antioxidant enzymes in oxidative stress—superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx). Med J SDU 2019; 26: 362–369.

75.

Shukla

Srivastava

Shankar

, et al. Oxidative stress and antioxidant status in high-risk prostate cancer subjects. Diagnostics (Basel) 2020; 10: E126.

76.

Stefek

Sotnikova

Okruhlicova

, et al. Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium. Acta Diabetol 2000; 37: 111–117.

77.

Kumar

Prasad

Sitasawad

. Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats. PLoS One 2013; 8: e67009.

78.

Tchamgoue

Tchokouaha

LRY

Tsabang

, et al. Costus afer protects cardio-, hepato-, and reno-antioxidant status in streptozotocin-intoxicated wistar rats. Biomed Res Int 2018; 2018: 4907648.

79.

Kotrikadze

Alibegashvili

Zibzibadze

, et al. Activity and content of antioxidant enzymes in prostate tumors. Exp Oncol 2008; 30: 244–247.

80.

Taheri

Djalali

Saedisomeolia

, et al. The relationship between the activities of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. Diabetes Metab Disord 2012; 11: 3.

81.

Gobbo

Costa

CFP

Silva

DGH

, et al. Effect of melatonin intake on oxidative stress biomarkers in male reproductive organs of rats under experimental diabetes. Oxid Med Cell Longev 2015; 2015: 614579.

82.

Vilela

Peixoto

Teixeira

, et al. The role of metformin in controlling oxidative stress in muscle of diabetic rats. Oxid Med Cell Longev 2016; 2016: 6978625.

83.

Volkovova

Chorvathova

Jurcovlcova

, et al. Antioxidative state of the myocardium and kidneys in acute diabetic rats. Physiol Res 1993; 42: 251–255.

84.

Bułdak

Łabuzek

Bułdak

, et al. Metformin affects macrophages’ phenotype and improves the activity of glutathione peroxidase, superoxide dismutase, catalase and decreases malondialdehyde concentration in a partially AMPK-independent manner in LPS-stimulated human monocytes/macrophages. Pharmacol Rep 2014; 6: 418–429.

85.

McGill

. The past and present of serum aminotransferases and the future of liver injury biomarkers. EXCLI J 2016; 15: 817–828.

86.

Barman

Srinivasan

. Attenuation of oxidative stress and cardioprotective effects of zinc supplementation in experimental diabetic rats. Br J Nutr 2017; 117: 335–350.

87.

Bayramoglu

Senturk

Bayramoglu

, et al. Carvacrol partially reverses symptoms of diabetes in STZ-induced diabetic rats. Cytotechnology 2014; 66: 251–257.

88.

Yanardag

Ozsoy-Sacan

Bolkent

, et al. Protective effects of metformin treatment on the liver injury of streptozotocin-diabetic rats. Hum Exp Toxicol 2005; 24: 129–135.

89.

Chan

FKM

Moriwaki

De Rosa

, Detection of necrosis by release of lactate dehydrogenase (LDH) activity. Methods Mol Biol 2013; 979: 65–70.

90.

Zager

Johnson

Becker

. Renal cortical lactate dehydrogenase: a useful, accurate, quantitative marker of in vivo tubular injury and acute renal failure. PLoS One 2013; 8: e66776.

91.

Tamariz

Hare

. Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation 2015; 131: 1741–1744.

92.

Landmesser

Spiekermann

Dikalov

, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073–3078.

93.

Farshid

Tamaddonfard

Moradi-Arzeloo

, et al. The effects of crocin, insulin and their co-administration on the heart function and pathology in streptozotocin-induced diabetic rats. Avicenna J Phytomed 2016; 6: 658–670.

94.

Aliciguzel

Ozen

Aslan

, et al. Activities of xanthine oxidoreductase and antioxidant enzymes in different tissues of diabetic rats. J Lab Clin Med 2003; 142: 172–177.

95.

Cosić

Antić

Pesić

, et al.

Monotherapy with metformin: does it improve hypoxia in type 2 diabetic patients?

Clin Chem Lab Med 2001; 38: 818–821.